Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice

Therapeutic failures attributed to medical management of cystic echinococcosis (CE) with albendazole (ABZ) have been primarily linked to the poor drug absorption rate resulting in low drug level in plasma and hydatid cysts. Lipid nanocapsules (LNCs) represent nanocarriers designed to encapsulate lip...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pensel, P.E., Ullio Gamboa, G., Fabbri, J., Ceballos, L., Sanchez Bruni, S., Alvarez, L.I., Allemandi, D., Benoit, J.P., Palma, S.D., Elissondo, M.C.
Formato:	JOUR
Materias:	Albendazole Cystic echinococcosis Echinococcus granulosus Lipid nanocapsules albendazole lipid nanocapsule nanocapsule unclassified drug anthelmintic agent lipid bioavailability concentration (composition) drug medical geography parasitic disease rodent animal experiment animal model area under the curve Article controlled study drug bioavailability drug blood level drug dosage form comparison drug efficacy drug exposure drug formulation echinococcosis female in vitro study maximum plasma concentration mouse nanoencapsulation nonhuman time to maximum plasma concentration animal drug delivery system medicinal chemistry oral drug administration Animalia Mus Administration, Oral Animals Anthelmintics Biological Availability Chemistry, Pharmaceutical Drug Delivery Systems Echinococcosis Female Lipids Mice Nanocapsules
Acceso en línea:	http://hdl.handle.net/20.500.12110/paper_0001706X_v152_n_p185_Pensel
Aporte de:	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

id	todo:paper_0001706X_v152_n_p185_Pensel
record_format	dspace
spelling	todo:paper_0001706X_v152_n_p185_Pensel2023-10-03T13:51:42Z Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice Pensel, P.E. Ullio Gamboa, G. Fabbri, J. Ceballos, L. Sanchez Bruni, S. Alvarez, L.I. Allemandi, D. Benoit, J.P. Palma, S.D. Elissondo, M.C. Albendazole Cystic echinococcosis Echinococcus granulosus Lipid nanocapsules albendazole lipid nanocapsule nanocapsule unclassified drug albendazole anthelmintic agent lipid bioavailability concentration (composition) drug lipid medical geography parasitic disease rodent animal experiment animal model area under the curve Article controlled study drug bioavailability drug blood level drug dosage form comparison drug efficacy drug exposure drug formulation echinococcosis female in vitro study maximum plasma concentration mouse nanoencapsulation nonhuman time to maximum plasma concentration animal bioavailability drug delivery system echinococcosis Echinococcus granulosus medicinal chemistry oral drug administration Animalia Echinococcus granulosus Mus Administration, Oral Albendazole Animals Anthelmintics Biological Availability Chemistry, Pharmaceutical Drug Delivery Systems Echinococcosis Echinococcus granulosus Female Lipids Mice Nanocapsules Therapeutic failures attributed to medical management of cystic echinococcosis (CE) with albendazole (ABZ) have been primarily linked to the poor drug absorption rate resulting in low drug level in plasma and hydatid cysts. Lipid nanocapsules (LNCs) represent nanocarriers designed to encapsulate lipophilic drugs, such as ABZ. The goals of the current work were: (i) to characterize the plasma and cyst drug exposure after the administration of ABZ as ABZ-LNCs or ABZ suspension (ABZ-SUSP) in mice infected with Echinococcus granulosus, and ii) to compare the clinical efficacies of both ABZ formulations. Enhanced ABZ sulphoxide (ABZ-SO) concentration profiles were obtained in plasma and cysts from ABZ-LNC treated animals. ABZSO exposure (AUC0-LOQ) was significantly higher in plasma and cyst after the ABZ-LNC treatments, both orally and subcutaneously, compared to that observed after oral administration of ABZ-SUSP. Additionally, ABZSO concentrations measured in cysts from ABZ-LNC treated mice were 1.7-fold higher than those detected in plasma. This enhanced drug availability correlated with an increased efficacy against secondary CE in mice observed for the ABZ-LNCs, while ABZ-SUSP did not reach differences with the untreated control group. This new pharmacotechnically-based strategy could be a potential alternative to improve the treatment of human CE. © 2015 Elsevier B.V. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_0001706X_v152_n_p185_Pensel
institution	Universidad de Buenos Aires
institution_str	I-28
repository_str	R-134
collection	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic	Albendazole Cystic echinococcosis Echinococcus granulosus Lipid nanocapsules albendazole lipid nanocapsule nanocapsule unclassified drug albendazole anthelmintic agent lipid bioavailability concentration (composition) drug lipid medical geography parasitic disease rodent animal experiment animal model area under the curve Article controlled study drug bioavailability drug blood level drug dosage form comparison drug efficacy drug exposure drug formulation echinococcosis female in vitro study maximum plasma concentration mouse nanoencapsulation nonhuman time to maximum plasma concentration animal bioavailability drug delivery system echinococcosis Echinococcus granulosus medicinal chemistry oral drug administration Animalia Echinococcus granulosus Mus Administration, Oral Albendazole Animals Anthelmintics Biological Availability Chemistry, Pharmaceutical Drug Delivery Systems Echinococcosis Echinococcus granulosus Female Lipids Mice Nanocapsules
spellingShingle	Albendazole Cystic echinococcosis Echinococcus granulosus Lipid nanocapsules albendazole lipid nanocapsule nanocapsule unclassified drug albendazole anthelmintic agent lipid bioavailability concentration (composition) drug lipid medical geography parasitic disease rodent animal experiment animal model area under the curve Article controlled study drug bioavailability drug blood level drug dosage form comparison drug efficacy drug exposure drug formulation echinococcosis female in vitro study maximum plasma concentration mouse nanoencapsulation nonhuman time to maximum plasma concentration animal bioavailability drug delivery system echinococcosis Echinococcus granulosus medicinal chemistry oral drug administration Animalia Echinococcus granulosus Mus Administration, Oral Albendazole Animals Anthelmintics Biological Availability Chemistry, Pharmaceutical Drug Delivery Systems Echinococcosis Echinococcus granulosus Female Lipids Mice Nanocapsules Pensel, P.E. Ullio Gamboa, G. Fabbri, J. Ceballos, L. Sanchez Bruni, S. Alvarez, L.I. Allemandi, D. Benoit, J.P. Palma, S.D. Elissondo, M.C. Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice
topic_facet	Albendazole Cystic echinococcosis Echinococcus granulosus Lipid nanocapsules albendazole lipid nanocapsule nanocapsule unclassified drug albendazole anthelmintic agent lipid bioavailability concentration (composition) drug lipid medical geography parasitic disease rodent animal experiment animal model area under the curve Article controlled study drug bioavailability drug blood level drug dosage form comparison drug efficacy drug exposure drug formulation echinococcosis female in vitro study maximum plasma concentration mouse nanoencapsulation nonhuman time to maximum plasma concentration animal bioavailability drug delivery system echinococcosis Echinococcus granulosus medicinal chemistry oral drug administration Animalia Echinococcus granulosus Mus Administration, Oral Albendazole Animals Anthelmintics Biological Availability Chemistry, Pharmaceutical Drug Delivery Systems Echinococcosis Echinococcus granulosus Female Lipids Mice Nanocapsules
description	Therapeutic failures attributed to medical management of cystic echinococcosis (CE) with albendazole (ABZ) have been primarily linked to the poor drug absorption rate resulting in low drug level in plasma and hydatid cysts. Lipid nanocapsules (LNCs) represent nanocarriers designed to encapsulate lipophilic drugs, such as ABZ. The goals of the current work were: (i) to characterize the plasma and cyst drug exposure after the administration of ABZ as ABZ-LNCs or ABZ suspension (ABZ-SUSP) in mice infected with Echinococcus granulosus, and ii) to compare the clinical efficacies of both ABZ formulations. Enhanced ABZ sulphoxide (ABZ-SO) concentration profiles were obtained in plasma and cysts from ABZ-LNC treated animals. ABZSO exposure (AUC0-LOQ) was significantly higher in plasma and cyst after the ABZ-LNC treatments, both orally and subcutaneously, compared to that observed after oral administration of ABZ-SUSP. Additionally, ABZSO concentrations measured in cysts from ABZ-LNC treated mice were 1.7-fold higher than those detected in plasma. This enhanced drug availability correlated with an increased efficacy against secondary CE in mice observed for the ABZ-LNCs, while ABZ-SUSP did not reach differences with the untreated control group. This new pharmacotechnically-based strategy could be a potential alternative to improve the treatment of human CE. © 2015 Elsevier B.V.
format	JOUR
author	Pensel, P.E. Ullio Gamboa, G. Fabbri, J. Ceballos, L. Sanchez Bruni, S. Alvarez, L.I. Allemandi, D. Benoit, J.P. Palma, S.D. Elissondo, M.C.
author_facet	Pensel, P.E. Ullio Gamboa, G. Fabbri, J. Ceballos, L. Sanchez Bruni, S. Alvarez, L.I. Allemandi, D. Benoit, J.P. Palma, S.D. Elissondo, M.C.
author_sort	Pensel, P.E.
title	Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice
title_short	Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice
title_full	Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice
title_fullStr	Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice
title_full_unstemmed	Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice
title_sort	cystic echinococcosis therapy: albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice
url	http://hdl.handle.net/20.500.12110/paper_0001706X_v152_n_p185_Pensel
work_keys_str_mv	AT penselpe cysticechinococcosistherapyalbendazoleloadedlipidnanocapsulesenhancetheoralbioavailabilityandefficacyinexperimentallyinfectedmice AT ulliogamboag cysticechinococcosistherapyalbendazoleloadedlipidnanocapsulesenhancetheoralbioavailabilityandefficacyinexperimentallyinfectedmice AT fabbrij cysticechinococcosistherapyalbendazoleloadedlipidnanocapsulesenhancetheoralbioavailabilityandefficacyinexperimentallyinfectedmice AT ceballosl cysticechinococcosistherapyalbendazoleloadedlipidnanocapsulesenhancetheoralbioavailabilityandefficacyinexperimentallyinfectedmice AT sanchezbrunis cysticechinococcosistherapyalbendazoleloadedlipidnanocapsulesenhancetheoralbioavailabilityandefficacyinexperimentallyinfectedmice AT alvarezli cysticechinococcosistherapyalbendazoleloadedlipidnanocapsulesenhancetheoralbioavailabilityandefficacyinexperimentallyinfectedmice AT allemandid cysticechinococcosistherapyalbendazoleloadedlipidnanocapsulesenhancetheoralbioavailabilityandefficacyinexperimentallyinfectedmice AT benoitjp cysticechinococcosistherapyalbendazoleloadedlipidnanocapsulesenhancetheoralbioavailabilityandefficacyinexperimentallyinfectedmice AT palmasd cysticechinococcosistherapyalbendazoleloadedlipidnanocapsulesenhancetheoralbioavailabilityandefficacyinexperimentallyinfectedmice AT elissondomc cysticechinococcosistherapyalbendazoleloadedlipidnanocapsulesenhancetheoralbioavailabilityandefficacyinexperimentallyinfectedmice
_version_	1807314698865999872

Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice

Ejemplares similares